ChiCTR-OCH-13003951
结束
/
/
/
2013-12-02
/
/
Ischemic mitral regurgitation post first episode of myocardial infarction
實時三維超聲心動圖在缺血性功能性關閉不全的二尖瓣單張適應的前瞻性臨床研究
實時三維超聲心動圖在缺血性功能性關閉不全的二尖瓣單張適應的前瞻性臨床研究
1. To confirm the clinical occurence of mitral leaflet adaptation in IMR by prospectively following up 2 MI cohorts, one with IMR, another without, using RT3DE to track changes in mitral leaflet, annular and left ventricular geometry from the acute to chronic phase of the disease; 2. To define the natural history of mitral leaflet adaptation with regard to its incidence, onset timing, durability, and extent by following up the study population for 1 year; 3. To test the hypothesis that inadequate leaflet adaptive enlargement to compensate for leaflet tethering contributes to the development of IMR by prospectively comparing IMR + and IMR- groups; 4. To explore the interactions between adaptive structural alteration taking placing in the mitral leaflets, annulus, and left ventricle, and their relationships with the development of IMR; 5. To identify potential factor(s) including clinical characteristics, echo cardiographic feathers, and therapeutic measures that may affect the occurrence and degree of mitral leaflet adaptation.
队列研究
其它
not applicable
/
RGC-GRF
/
50;75
/
2013-02-18
2016-10-31
/
Prospectively enrolled patients hospitalized for first episode of acute MI. 1. Diagnosis of MI is based on cardiac pain, newly developed Q waves, ST elevation/depression on ECG, and typical rise and fall of cardiac biomarkers (Troponin and/or CPK); 2. Patient will receive standard management for acute MI including medications and/or revascularization according to physician discretion; 3. All MI patients meeting the inclusion criteria will have serial transthoracic echocardiographic study including 2D/3D/TDI within 72 hours, in 7-14 days, and at 1 month post-MI. Patients will be separated into 2 groups based on presence or absence of IMR at 1 month, as defined by color flow imaging. The rationale of using 1 month for group separation is to avoid inclusion of transient MR due to acute ischemia, and is based on accepted definition of IMR in large epidemiological studies (2-4), as well as the time frame of ML adaptation in animal studies (13, 14, 17); 4. Healthy controls with normal history, physical examination and echocardiography matched for age, gender and body surface area will be enrolled from the community.;
请登录查看Prior MI or known left ventricular dysfunction, previous cardiac surgery, papillary muscle rupture, MR due to primary organic valve disease, associated aortic valve or congenital heart disease, poor image quality, and atrial fibrillation.;
请登录查看Research Grant Council
/
Research Grant Council的其他临床试验
The Chinese University of Hong Kong的其他临床试验
- Feasibility, Acceptability and Effectiveness of a Tailored Multidimensional Intervention for Dementia Family Caregivers in Caregiving and Mental Health Crisis: A Pilot Randomised Controlled Trial
- One-step Rehydration Thawing Method in Frozen Embryo Transfer: A pragmatic randomized controlled clinical trial (ORT-FET-RCT)
- Feasibility and Acceptability of Cognitive Behavioural Stress Management Intervention (JoyMUM) for Pregnant Women: A Pilot Randomised Controlled Trial
- Building Resilience Against Rising Temperature - The Effect of High-Intensity Interval Exercise (HIIE) on Heat Tolerance, Thermoregulatory Adaptation, and Physical Fitness: A Comparative Randomized Controlled Trial
- The effect of Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors on Diabetic Retinal Disease
- 运动与脑刺激疗愈:促进居住于分间楼宇单位的注意力缺陷多动障碍儿童症状控制的三臂随机对照试验
- Effects of Care partner Online Programme for Managing BPSD and Enhancing Wellbeing (COPE‑BPSD)
- Air purifier and respiratory outcomes in childhood asthma in compromised housing environments: a hybrid effectiveness-implementation trial
- To investigate structural variations (SVs) in autism spectrum disorder (ASD) and related endophenotypes
- Young Adult Community Health Advisor (YACHA)-led Project to Promote Anti-drug Awareness among South Asian Youths and their Family in Hong Kong
- Effects of High-Intensity Interval Training on Physical Fitness, Cognitive and Mental Health in Hong Kong Adolescents with Intellectual Disabilities: A Cluster-Randomized Controlled Trial
- A self-determination theory-based interprofessional intervention to improve diabetes management in the primary health care setting of Hong Kong
- The Effects of Low‐ and High‐Glycemic Index Sport Nutrition Bars on Metabolism and High‐Intensity Interval Training Responses
- An innovative approach to combine intermittent dieting (INTD) with high-intensity interval exercise (HIIE) for curbing central obesity: A comparative randomized controlled trial
- Effectiveness of acceptance-based diabetes self-management (ACT-DSM) for adults with type 2 diabetes for improving diabetes distress and glycaemic control: A randomised controlled trial
- Effects of GABA with Butyrate, GABA/Butyrate-producing Synbiotics on Pain Relief in Fibromyalgia: A Phase II, Multi-Center, Double-Blinded, Randomized-Controlled Trial
- 一项关于声刺激增强慢波睡眠以改善失眠障碍睡眠质量的探索性研究
- The effects of art therapy-based intervention on anxiety children with haematological cancers: a randomised controlled trial
- Effectiveness of Digital CBT-I and BT-I combined ACT for Insomnia and Anxiety Symptoms in Youth: A Randomised Control Trial
- An evidence-based advance care planning programme to promote end-of-life care planning among patients with advanced diseases in the Emergency Department – a feasibility randomised controlled trial
最新临床资讯
-
诺华:CFB抑制剂终止狼疮肾炎二期临床
医药笔记2026-10-17
-
泽安生物医药:实体瘤MCE启动一期临床
医药笔记2026-10-17
-
药明康德2026-10-17
-
沃森生物2026-10-16
-
罕见病信息网2026-10-16
-
武警特色医学中心2026-10-16
-
生物经纬2026-10-16
-
良医汇肿瘤资讯2026-10-16
-
BioMed科技2026-10-16
-
蒲公英资讯2026-10-16
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-10-26
-
2026-10-25
-
2026-10-25
-
摩熵咨询 33 51
-
摩熵咨询 20 3
-
摩熵咨询 20 10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
-
颁布机构:国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构:国家药品监督管理局 2026-09-10
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-10-23
-
2026-10-23
-
2026-10-21
-
摩熵咨询 35 83
-
摩熵咨询 28 71
-
摩熵咨询 34 47
-
颁布机构:国家药品监督管理局 2026-10-19
-
颁布机构:国家市场监督管理总局 2026-10-16
-
颁布机构:国家市场监督管理总局 2026-09-30
